Cyclo Therapeutics (NASDAQ:CYTH – Get Free Report) and Replimune Group (NASDAQ:REPL – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, earnings, dividends and risk.
Volatility and Risk
Cyclo Therapeutics has a beta of -0.3, meaning that its stock price is 130% less volatile than the S&P 500. Comparatively, Replimune Group has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500.
Earnings and Valuation
This table compares Cyclo Therapeutics and Replimune Group’s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cyclo Therapeutics | $1.08 million | 33.66 | -$20.06 million | ($1.00) | -1.27 |
| Replimune Group | N/A | N/A | -$215.79 million | ($3.24) | -2.78 |
Analyst Recommendations
This is a summary of current ratings for Cyclo Therapeutics and Replimune Group, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cyclo Therapeutics | 0 | 0 | 3 | 0 | 3.00 |
| Replimune Group | 0 | 0 | 3 | 0 | 3.00 |
Cyclo Therapeutics currently has a consensus price target of $3.20, suggesting a potential upside of 151.97%. Replimune Group has a consensus price target of $16.67, suggesting a potential upside of 85.19%. Given Cyclo Therapeutics’ higher probable upside, equities research analysts clearly believe Cyclo Therapeutics is more favorable than Replimune Group.
Profitability
This table compares Cyclo Therapeutics and Replimune Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cyclo Therapeutics | -1,720.76% | -2,741.89% | -253.06% |
| Replimune Group | N/A | -48.62% | -39.47% |
Insider & Institutional Ownership
68.6% of Cyclo Therapeutics shares are held by institutional investors. Comparatively, 92.5% of Replimune Group shares are held by institutional investors. 29.8% of Cyclo Therapeutics shares are held by insiders. Comparatively, 20.6% of Replimune Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
About Replimune Group
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Receive News & Ratings for Cyclo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
